Document is current
Any future updates will be listed below
-
Authors
Liu, Kang https://orcid.org/0000-0002-4683-9501
Cheng, Li https://orcid.org/0000-0002-1286-9403
Zhu, Kun
Wang, Jinhu https://orcid.org/0000-0002-7749-2475
Shu, Qiang https://orcid.org/0000-0002-4106-6255
-
Funding
Funding for this research was provided by:
Zhejiang Chinese Medical University (2021E10014)
Zhejiang Provincial Program for the Cultivation of High-level Innovative Health talents 2016-6 (Q.S.), the National Natural Science Foundation of China
- License Information
-
More Information
Article History
Received: 24 November 2021
Revised: 26 February 2022
Accepted: 15 March 2022
First Online: 28 March 2022
Competing interests
: The authors declare no competing interests.
: The use of human lung adenocarcinoma tissue microarray (HLugA180Su04) in this study was purchased from Outdo Biotech Company (Shanghai, China) and approved by the Medical Ethics Committee of Outdo Biotech Company (Permit number: SHYJS-CP-1610002). All animal experiments in this study were approved by the Experimental Animal Ethics Committee of Zhejiang University.
